<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04865978</url>
  </required_header>
  <id_info>
    <org_study_id>00100</org_study_id>
    <nct_id>NCT04865978</nct_id>
  </id_info>
  <brief_title>Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices</brief_title>
  <acronym>DOAC LVAD</acronym>
  <official_title>Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palak Shah, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inova Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, controlled, open label, trial of LVAD patients with 1:1&#xD;
      randomization to either apixaban or warfarin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study will be a prospective, randomized, controlled, open label, trial of&#xD;
      HeartMate 3 (HM3) LVAD patients with 1:1 randomization to either apixaban or warfarin. All&#xD;
      patients will be treated with aspirin 81 mg daily as per the LVAD manufacturer instructions&#xD;
      for use (IFU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, prospective, randomized, 1:1 intervention arm versus control</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from death or hemocompatibility related adverse events (stroke, device thrombosis, bleeding, aortic root thrombus, and arterial non-CNS thromboembolism)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Composite endpoint in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival free of any stroke</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of ischemic stroke</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of hemorrhagic stroke</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of device thrombosis</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of gastrointestinal bleeding</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of major non-gastrointestinal bleeding</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of aortic root thrombus</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The rate of primary and secondary outcomes will be evaluated in subgroups of patients within 3 months of implant versus greater than 3 months from LVAD implant</measure>
    <time_frame>24 weeks</time_frame>
    <description>Compared between each study arm</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Patients randomized to apixaban will be started on a dose of 5 mg BID.</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Patients randomized to warfarin will be started on a dose per institutional protocol and titrated to an INR goal of 2.0 - 2.5.</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LVAD implant</intervention_name>
    <description>Subjects will undergo HeartMate 3 LVAD implant prior to randomization</description>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients implanted with a HeartMate 3 LVAD&#xD;
&#xD;
          2. Age 18 or greater and able to provide written informed consent&#xD;
&#xD;
          3. Females of childbearing age must agree to adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of post-LVAD device thrombosis, stroke, or gastrointestinal bleeding&#xD;
&#xD;
          2. Patients who are bridge to transplant and a current UNOS status 1-3&#xD;
&#xD;
          3. Ongoing inotrope therapy after LVAD (e.g., milrinone, dobutamine, epinephrine)&#xD;
&#xD;
          4. Permanent right ventricular assist device at the time of LVAD implant&#xD;
&#xD;
          5. Patients with a mechanical heart valve&#xD;
&#xD;
          6. Patients with end-stage renal disease on dialysis&#xD;
&#xD;
          7. Pregnant patients&#xD;
&#xD;
          8. Known history of ischemic stroke, intracranial bleed, or neurosurgery within 3 months&#xD;
&#xD;
          9. Known history of intracerebral arteriovenous malformation, cerebral aneurysm or mass&#xD;
             lesions of the central nervous system.&#xD;
&#xD;
         10. Recent (&lt;48 hours) or planned spinal or epidural anesthesia or puncture&#xD;
&#xD;
         11. Prior history of known thrombophilia (e.g., factor V Leiden, prothrombin gene&#xD;
             mutation, protein C or S deficiency, antithrombin 3 deficiency, hyperhomocysteinemia,&#xD;
             antiphospholipid antibody syndrome) or indication for higher INR goal (&gt;2.5) with&#xD;
             warfarin.&#xD;
&#xD;
         12. Thrombolysis within the previous 7 days&#xD;
&#xD;
         13. Patients with an allergy or contraindication to aspirin, warfarin, or apixaban&#xD;
&#xD;
         14. Patients on antiplatelet therapy other than aspirin (e.g., clopidogrel, prasugrel,&#xD;
             ticagrelor, dipyridamole, or pentoxifylline)&#xD;
&#xD;
         15. Patients on combined P-glycoprotein and strong CPY3A4 inhibitors or inducers (e.g.,&#xD;
             fluconazole, posaconazole, rifampin)&#xD;
&#xD;
         16. Known bleeding within the last 30 days requiring emergency room presentation or&#xD;
             hospitalization&#xD;
&#xD;
         17. Known history of an inherited bleeding disorder (e.g., hemophilia, von Willebrand&#xD;
             disease)&#xD;
&#xD;
         18. Patients with active bleeding or a hemoglobin &lt; 8.0 g/dl&#xD;
&#xD;
         19. Total bilirubin &gt; 2.0 mg/dl, shock liver, hepatic encephalopathy, or biopsy proven&#xD;
             liver cirrhosis&#xD;
&#xD;
         20. INR &gt; 2.0 not due to anticoagulation therapy&#xD;
&#xD;
         21. Platelet count &lt;100,000 cells/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Palak Shah, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inova Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhruga Shah, RN</last_name>
    <phone>703-776-2828</phone>
    <email>bhruga.shah@inova.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bhruga Shah, RN</last_name>
      <phone>703-776-2828</phone>
      <email>Bhruga.Shah@inova.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Inova Health System</investigator_affiliation>
    <investigator_full_name>Palak Shah, MD</investigator_full_name>
    <investigator_title>Medical Director, Mechanical Circulatory Support</investigator_title>
  </responsible_party>
  <keyword>ventricular assist device</keyword>
  <keyword>LVAD</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>apixaban</keyword>
  <keyword>warfarin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

